Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News PureTech Health ADR Representing 10 Ord Shs PRTC

Healthcare Biotechnology
PureTech Health plc is a clinical stage biotherapeutics company dedicated to giving life to new classes of medicine to change the lives of patients with devastating diseases. The Company's R&D engine has resulted in the development of around 29 therapeutics and therapeutic candidates, including two that have received both United States Food and Drug Administration (FDA) clearance and European... see more

Recent & Breaking News (NDAQ:PRTC)

PureTech Announces the Appointment of George Farmer, Ph.D., as Chief Financial Officer

Business Wire January 5, 2021

PureTech to Present at 38th Annual J.P. Morgan Healthcare Conference and Other Conferences

Business Wire December 21, 2020

PureTech Advances Wholly Owned Candidate LYT-200 into Phase 1 Trial for Potential Treatment of Metastatic Solid Tumors

Business Wire December 11, 2020

PureTech Initiates Phase 2a trial of LYT-100 (Deupirfenidone) in Lymphedema

Business Wire December 10, 2020

Follica Announces Pilot Study for Female Pattern Hair Loss Published in International Journal of Women's Dermatology

Business Wire December 9, 2020

PureTech Founded Entity Follica Announces Pilot Study for Female Pattern Hair Loss Published in International Journal of Women's Dermatology

Business Wire December 9, 2020

PureTech Initiates Phase 2 trial of LYT-100 (Deupirfenidone) in Long COVID Respiratory Complications and Related Sequelae

Business Wire December 3, 2020

PureTech to Host Virtual R&D Day for Investors on December 11, 2020

Business Wire November 30, 2020

PureTech Founded Entity Vedanta Biosciences Appoints Troy Ignelzi, Chief Financial Officer at Karuna Therapeutics, to its Board of Directors

Business Wire November 24, 2020

Vedanta Biosciences Appoints Troy Ignelzi, Chief Financial Officer at Karuna Therapeutics, to Its Board of Directors

Business Wire November 24, 2020

PureTech's LYT-100 (Deupirfenidone) Demonstrates Tolerability and Pharmacokinetic Proof-of-Concept in Phase 1 Multiple Ascending Dose and Food Effect Study

Business Wire November 18, 2020

PureTech to Present at Three Upcoming Investor Conferences

Business Wire November 16, 2020